The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.
PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...
We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...
Kennedy Jr. was pressed to clarify his views on vaccines, abortion and public health priorities in the first of two senate ...
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB), a commercial-stage biopharmaceutical company with a "GOOD" InvestingPro Financial ...
Hosted on MSN6d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, until January 2028, to comply with the change. Red 3, also known as ...
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year. Even though JNJ has displayed an improving track record of beating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback